FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileGenmab A/S
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GNMSF
Genmab A/S Stock AnalysisComprehensive stock analysis for Genmab A/S (GNMSF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisGNMSF
GNMSF
Genmab A/S
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GNMSF
  1. Home
  2. Stocks
  3. Genmab A/S

Genmab A/S

🇺🇸GNMSF•OTC

Genmab A/S

🇺🇸GNMSF•OTC
Market cap
$17.86B
P/E ratio
42.85

Your view on GNMSF

Mkt Cap
$17.86B
P/E
42.85
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Genmab A/S

Industry
Biotechnology
Sector
Healthcare
CEO
Jan van de Winkel
Headquarters
Kalvebod Brygge 43, Copenhagen, DK
Industry
Biotechnology
Sector
Healthcare
CEO
Jan van de Winkel
Headquarters
Kalvebod Brygge 43, Copenhagen, DK
Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.

The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.

In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.

It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Genmab A/S from FRC's valuation model, read against the market price. GNMSF last traded at $290.00, 42.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Genmab A/S. Starting points for Genmab A/S: P/E 42.8, EPS $11.90, beta 0.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Genmab A/S. Genmab A/S does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Genmab A/S. Trailing twelve-month EPS for Genmab A/S stands at $11.90. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Genmab A/S. Genmab A/S has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold GNMSF12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NTLAIntellia Therapeutics, Inc.HealthcareNASDAQ$1.4B
NTRBNutriband Inc.HealthcareNASDAQ$59.8M
NTRBWNutriband Inc.HealthcareNASDAQ$76.8M
NTRRNeutra Corp.HealthcareOTC$291,790
NURPFNeuren Pharmaceuticals LimitedHealthcareOTC$1.1B
NUVBNuvation Bio Inc.HealthcareNYSE$1.3B
NUZ.AXNeurizon Therapeutics LimitedHealthcareASX—
NVAXNovavax, Inc.HealthcareNASDAQ$1.2B
NVCTNuvectis Pharma, Inc.HealthcareNASDAQ$666.8M
NWBONorthwest Biotherapeutics, Inc.HealthcareOTC$359.4M
NWPHFNewron Pharmaceuticals S.p.A.HealthcareOTC$239.5M
NXTCNextCure, Inc.HealthcareNASDAQ$29.5M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Genmab A/S. Coverage tracks Genmab A/S within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Genmab A/S.

GNMSF AnalysisFair
Past
5
Growth
1
Health
3
Profit
3
Value
1